Search results
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Zacks via Yahoo Finance· 5 days agoPfizer (PFE) expects its operational revenues to improve, driven by its in-line products like...
Pfizer lifts profit view on cost cuts, demand for COVID products
Reuters· 3 days agoSales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion deal...
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Investor's Business Daily· 2 days agoFurther, the company expects "higher vaccination uptake" in the U.S. if its updated Covid vaccine is...
Supreme Court rejected military chaplains' lawsuit saying their careers were ruined after refusing...
Business Insider· 3 days agoThe Supreme Court denied military chaplains' lawsuit claiming retaliation for refusing the COVID-19 ...
Pfizer profits drop on lower Covid-19 product sales
Digital Journal· 3 days agoPfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 2 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline By Investing.com
Investing.com· 3 days agoDespite a 19% decline in total company revenues to $14.9 billion, primarily due to the reduced...
Pfizer Jumps On 'Massive' First-Quarter Upside Thanks To Paxlovid Surprise
Investor's Business Daily· 3 days agoThat was partly due to a one-time $771 million infusion after the U.S. government returned 5.1...
Pfizer’s first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Market Watch· 3 days agoAn expected drop in COVID-19-related product sales, including antiviral Paxlovid and vaccine...
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Motley Fool via Yahoo Finance· 2 days agoPrevnar: The pneumococcal vaccine should continue being a cash cow for the drugmaker despite potential competition from Merck's vaccine V116 in the adult...